Pliant Therapeutics Inc
PLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$68.73M
Close$
$0.27
76.6% downside
Current Fair Value
76.6% downsideOvervalued by 76.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $68.73 Million |
|---|---|
| Enterprise Value | $72.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 1.28 |
| Outstanding Shares | 61,919,233 |
Return
| Return on Equity | -62.81% |
|---|---|
| Return on Assets | -48.60% |
| Return on Invested Capital | -55.57% |
Valuation & Multiples
| P/E Ratio | -0.74 |
|---|---|
| PEG | 1.54 |
| Price to Sales | - |
| Price to Book Ratio | 0.57 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.75 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.5186▼ 56.55% |
|---|---|
| Total Calls | 61,900▲ 4.03% |
| Total Puts | 94,000▼ 24.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 77.68%▼ 2.70% |
|---|---|
| Total Invested | $54.83M▼ 12.24% |
| Investors Holding | 88▼ 6.00% |
ESG Score
No data
About Pliant Therapeutics Inc
CEO: Bernard Coulie